{"title":"IDDF2023-ABS-0145 HBeAg阴性、ALT正常、HBV DNA阳性的慢性乙型肝炎患者可从核苷类似物治疗中获益:一项长期随访的单中心回顾性研究结果","authors":"E. Chen, Jingdi Zhou, Fada Wang, Lanzhi Li","doi":"10.1136/gutjnl-2023-iddf.141","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"IDDF2023-ABS-0145 HBeAg negative chronic hepatitis B patients with normal ALT and positive HBV DNA can benefit from nucleos(t)ide analogue therapy: results of a single center retrospective study with long-term follow-up\",\"authors\":\"E. Chen, Jingdi Zhou, Fada Wang, Lanzhi Li\",\"doi\":\"10.1136/gutjnl-2023-iddf.141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9921,\"journal\":{\"name\":\"Chinese Journal of Clinical Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese Journal of Clinical Hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/gutjnl-2023-iddf.141\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Clinical Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/gutjnl-2023-iddf.141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
IDDF2023-ABS-0145 HBeAg negative chronic hepatitis B patients with normal ALT and positive HBV DNA can benefit from nucleos(t)ide analogue therapy: results of a single center retrospective study with long-term follow-up